AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2022
Aug 3, 2022
31523_dirs_2022-08-03_604af8f7-1b52-47c6-86c6-f17ee5924b6f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2022-08-01
Reporting Person: Crowley John F (Director, Executive Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-01 | Common Stock | S | 11346 | $9.962 | Disposed | 889179 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 64895 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.75 to $10.23 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.